GRF(1-29) raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
=== Flex bonds === The transition between catch and slip bonds have been modeled as molecular dissociation from two bond states along two pathways. Dissociation along each pathway alone results in a slip bond but at different rates. At low forces, dissociation occurs predominately along the fast pathway. Increasing force tilts the multi-dimensional energy landscape to switch the dissociation from fast pathway to slow pathway, manifesting catch bond. As dissociation along the slow pathway dominates, further increase in force accelerates dissociation, manifesting slip bond. This switching behavior is also called flex bond.
=== Forestry === In commercial forestry, the transplanting of crop trees to new locations often requires an accompanying ectomycorrhizal partner. This is especially true of trees that have a high degree of specificity for their mycobiont, or trees that are being planted far from their native habitat among novel fungal species. This has been repeatedly shown in plantations involving obligate ectomycorrhizal trees, such as Eucalyptus and Pinus species. Mass planting of these species often requires an inoculum of native EcM fungi for the trees to prosper. Sometimes ectomycorrhizal plantation species, such as pine and eucalyptus, are planted and promoted for their ability to act as a sink for atmospheric carbon. However, the ectomycorrhizal fungi of these species also tend to deplete soil carbon, making this use of plantations controversial.
A mixed dose commonly combines regular insulin, which is fast acting, with a longer acting insulin such as NPH. A mixed dose insulin schedule may be prescribed to provide both short-term and long-term coverage. mmol/L Millimoles per litre. The world-standard (excepting the US) designated SI unit for the measurement of blood sugar levels. It is the concentration by molecular weight in a set amount of liquid. Mononeuropathy A form of diabetic neuropathy affecting a single nerve. The eye is a common site for this form of nerve damage. See also: Neuropathy. Morbidity rate the rate at which Mortality rate the rate at which death occurs (usually used as a statistical shorthand in regard to an infection or other condition). Myocardial infarction heart attack. The words mean heart muscle blockage. Myo-inositol A substance in the cell that is thought to play a role in helping the nerves to work. Low levels of myo-inositol may be involved in diabetic neuropathy.
Sources: en.wikipedia.org
reuteri-and-tryptophan-diet for checkpoint inhibitor potentiation (6 Apr), doxycycline post-exposure prophylaxis against STIs (6 Apr), an engineered probiotic against alcohol-induced damage (11 Apr), phase 2 trialed AXA1125 against long COVID fatigue (14 Apr), review finds cranberry products useful against UTIs in women (17 Apr) (but is not suggested for older people, those have trouble emptying their bladder, or people who are pregnant), and macaques-tested low-intensity focus ultrasound delivery of AAV into brain regions against brain diseases (19 Apr). Progress in screening: an α-synuclein SAA (assay) against Parkinson's disease (12 Apr), and exogenously administered bioengineered sensors that amplify urinary cancer biomarkers for detection (24 Apr). Promising innovations relating to global challenges are reported: a laser-using drone-based methane plume localization method, approval of the first yeast-based cow-free dairy (Remilk), a Tor browser-equivalent Web browser for privacy-protected browsing when using a VPN (Mullvad browser), a concentrated solar-to-hydrogen device approaching viability, a method for fat tissue cultured meat, flexible organic solar cells on balloons in the 35 km stratosphere.
Ghana is a unitary presidential constitutional democracy with a parliamentary multi-party system that is dominated by two parties—the National Democratic Congress (NDC) and the New Patriotic Party (NPP). Ghana alternated between civilian and military governments until January 1993, when the military government gave way to the Fourth Republic of Ghana after presidential and parliamentary elections in late 1992. The 1992 constitution of Ghana divides powers among a commander-in-chief of the Ghana Armed Forces (President of Ghana), parliament (Parliament of Ghana), cabinet (Cabinet of Ghana), council of state (Ghanaian Council of State), and an independent judiciary (Judiciary of Ghana). The government is elected by universal suffrage after every four years. The 2012 Fragile States Index indicated that Ghana is ranked the 67th-least fragile state in the world and the fifth-least fragile state in Africa. Ghana ranked 112th out of 177 countries on the index. Ghana ranked as the 64th-least corrupt and politically corrupt country in the world out of all 174 countries ranked and ranked as the fifth-least politically corrupt country in Africa out of 53 countries in the 2012 Transparency International Corruption Perception Index. Ghana was ranked seventh in Africa out of 53 countries in the 2012 Ibrahim Index of African Governance. The Ibrahim Index is a comprehensive measure of African government, based on variables that reflect the success with which governments deliver essential political goods to its citizens.
She was active in that role for over ten years. During that time she was also elected into the Association of American Physicians. In 2015 Dr. Huttenlocher was inducted as a Member of the National Academy of Medicine "for her pioneering studies of cell migration and alterations of cell migration in human diseases." In 2017, Huttenlocher was awarded a UW2020 grant to support her project "Engineering leukocytes generated from human iPS cells to treat human disease." At the same time, she was also elected a Fellow of the American Society for Cell Biology. In May 2020, Huttenlocher was named the Anna Ruth Brummett Professor of Pediatrics and Medical Microbiology and Immunology Chair in honor of her "major contributions to the advancement of knowledge." The following year, she was part of a large team of researchers from the University of Wisconsin Carbone Cancer Center recognized with the Society for the Immunotherapy of Cancer’s Team Science Award for "long-standing contribution to the field of cancer immunotherapy over the past 35 years." Huttenlocher's recent research projects include "Cell migration and wound repair" and "Imaging immunometabolism in live animals during host defense." In 2023, Huttenlocher published the book "From Loss to Memory: Behind the Discovery of Synaptic Pruning". It describes the discovery of synaptic pruning and its current relevance to early learning, autism, schizophrenia and Alzheimer's disease.
Examination of remains of Homo erectus from Kenya, which are about 1.6 million years old, has revealed signs typical of yaws. The genetic analysis of the yaws causative bacteria—Treponema pallidum pertenue—has led to the conclusion that yaws is the most ancient of the four known Treponema diseases. All other Treponema pallidum subspecies probably evolved from Treponema pallidum pertenue. Yaws is believed to have originated in tropical areas of Africa and spread to other tropical areas of the world via immigration and the slave trade. The latter is likely the way it was introduced to Europe from Africa in the 15th century. The first unambiguous description of yaws was made by the Dutch physician Willem Piso. Yaws was clearly described in 1679 among African slaves by Thomas Sydenham in his epistle on venereal diseases, although he thought that it was the same disease as syphilis. The causative agent of yaws was discovered in 1905 by Aldo Castellani in ulcers of patients from Ceylon. The current English name is believed to be of Carib origin, from "yaya", meaning sore. Towards the end of the Second World War, yaws became widespread in the North of Malaya under Japanese occupation. After the country was liberated, the population was treated for yaws by injections of salvarsan, of which there was a great shortage, so only those with stage 1 were treated.
Sources: en.wikipedia.org
==== Comparisons ==== Its healing efficacy against ulceration is significantly greater than that of other zinc complexes, free L-carnosine, and zinc D-carnosine (which is not sold as a supplement to consumers). The pharmacological activity of zinc L-carnosine seems attributable mainly to zinc ion, presumably transported effectively into the ulcer by means of L-carnosine together with the action of L-carnosine itself. In contrast, a simple mixture of L-carnosine and zinc had a lesser effect, presumably due to rapid diffusion of L-carnosine and zinc ion in the entire stomach. Per preclinical data, zinc L-carnosine is superior to zinc sulfide for mucositis.
The two substrates of this enzyme are (S,S)-butane-2,3-diol and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (S)-acetoin, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (S,S)-butane-2,3-diol:NAD+ oxidoreductase. Other names in common use include L-butanediol dehydrogenase, L-BDH, and L(+)-2,3-butanediol dehydrogenase (L-acetoin forming). This enzyme participates in butanoic acid metabolism.
== History == Olaratumab was originally developed by ImClone Systems, which was acquired by Eli Lilly in 2008. A Phase I clinical trial was conducted in Japanese patients in September 2010, followed by a Phase II trial in 133 patients, starting in October 2010. In February 2015, the European Medicines Agency assigned olaratumab orphan drug status for the treatment of soft-tissue sarcoma. The European Commission granted a conditional marketing authorisation, based on the mentioned Phase II study, valid throughout the European Union on 9 November 2016. Previously considered a promising drug, the FDA granted olaratumab fast track designation, breakthrough therapy designation and priority review status. In October 2016, the US FDA issued an accelerated approval notice for use of olaratumab with doxorubicin to treat adults with certain types of soft-tissue sarcoma, based on the same study. A phase III trial completed in 2019, and unfortunately showed no benefit from the addition of olaratumab to doxorubicin. As noted above, these results led to withdrawal of approval in the United States and Europe.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.